Introduction
The papillary thyroid carcinoma (PTC) is the most frequent malignancy originating in the thyroid gland. With respect to gene alterations in carcinogenesis, PTCs have exceedingly low rates of loss of heterozygosity, with no specific region displaying a particularly high prevalence compared with follicular carcinomas [1] , but somatic rearrangement of the s RET proto-oncogene has been detected in 25-35% of PTCs in the Western World [2, 3] , and frequencies varied in Japanese cases (3-36%) [4] [5] [6] . Recently, BRAF mutations, i.e. alternative molecular events, have been detected in 0-83% of PTCs, [7] [8] [9] [10] . Finally, activated MAP kinase signaling caused by RET rearrangement, BRAF or RAS mutations, or other molecular alterations is thought to be essential for the induction of PTC [11] . However, the frequencies of gene alterations have been shown to differ in different ethnicities, reflecting different lifestyles, including nutrients such as iodine, and other mechanisms of PTC development and progression need to be identified.
The roles of DNA methylation in carcinogenesis have been highlighted for various types of cancers. Promotor hypermethylation of CpG islands has been shown to be an epigenetic change resulting in loss of function of responsive genes involved in cell cycle regulation and DNA repair. In PTCs, hypermethylation at exon 1 of p16 ing that the function of this gene may be lost during disease progression [12] . However, the knowledge on hypermethylation in PTCs is still insufficient.
In this study, a total of 39 tumors were evaluated using methylation-specific PCR (MSP) to assess hypermethylation in multiple genes implicated in regulatory processes, including p16 INK4a , p14 ARF , RB1 , p27 Kip1 and 0 6 -MGMT . We also investigated homozygous deletions of p16 INK4a and p14 ARF , and protein expression by immunohistochemistry. The results showed statistically significant correlations between alterations in specific genes and certain clinicopathological features of the tumors.
Materials and Methods
Tumor Samples and DNA Extraction Samples of 39 PTCs, consisting of conventional PTCs with well-differentiated histology, were obtained from the Department of Otolaryngology, Nara Medical University Hospital. Detailed clinicopathological data, e.g. age, sex, past history of chronic thyroid disease, tumor size, presence of regional lymph node metastasis, distant metastasis and clinical stage, were collected and summarized in table 1 . The patients comprised 9 males and 30 females, ranging in age from 12 to 79 years, with a mean of 54.1 years. Two had a past history of chronic thyroiditis, and 2 suffered from Graves' (Basedow's) disease. According to the TNM classification, 9 (23.1%) presented with stage I, 12 (30.8%) with stage II, 17 (43.6%) with stage III and 1 (2.6%) with stage IV lesions.
The tumor samples were all fixed in 10% buffered formalin and embedded in paraffin, cut at 4 m and stained with hematoxylin and eosin (HE) for histopathological evaluation, with especial focus on lymphocytic infiltration. DNA was extracted by methods described previously [13] .
Methylation-Specific PCR
MSP is sufficiently sensitive to detect a single methylated allele among 1,000 unmethylated ones [14] and, therefore, may be the most appropriate methodology for identifying DNA methylation patterns within CpG islands of p16 INK4a , p14 ARF , RB1 , p27 Kip1 and 0 6 -MGMT. MSP distinguishes unmethylated from methylated alleles based on sequence changes produced after bisulfite treatment of DNA, which converts only unmethylated cytosine to uracil, and subsequent PCR using primers designed for either methylated or unmethylated DNA. It was here performed using sodium bisulfite modification with a 'CpGenome' DNA modification kit (Intergen, Oxford, UK) according to the manufacturer's protocol with additional minor modification [15, 16] . The primer sequences and the detailed MSP conditions have been reported previously [14, [17] [18] [19] [20] [21] [22] . The regions analyzed for p16 INK4a , p14 ARF and 0 6 -MGMT were promoter regions of the transcriptional start site [14, 17, 23] . For RB1 and p27
Kip1
, the regions analyzed were promoter regions of the trans lational start site and exon 2, respectively [20, 22] . Control methylated (Intergen) and unmethylated DNA from blood samples of normal volunteers were also treated with bisulfite as positive and negative controls. Amplified products were subsequently elec tro pho re sed on 2% agarose gels and visualized by ethidium bromide staining.
Differential PCR for p14
ARF and p16 INK4a Deletions To detect homozygous deletions, differential PCRs were carried out. Duplex PCR was performed to generate a 149-bp fragment covering exon 1 ␤ of the p14 ARF gene, and a 204-bp exon fragment of p16 INK4a 1 ␣ , together with a 160-bp fragment of the GAPDH gene and a 187-bp fragment of ␤ -actin as internal controls, mainly to confirm the integrity of the template and also to assess contamination of samples by normal cells. Both sets of primers, for the control locus and the potentially deleted locus, were included in the PCR reaction mixture. DNA was amplified with 30 and 29 cycles of PCR for the p16 INK4a and p14 ARF genes, respectively. The primer sequences and detailed PCR conditions have been described previously [16, 24] . PCR products were analyzed on 8% acrylamide gels and photographed using a DC290 Zoom Digital Camera (Eastman Kodak, Rochester, N.Y., USA). Densitometry was performed using Kodak Digital Science ID Image Analysis software (version 3.5.2; Eastman Kodak). Samples presenting ! 20% of the control signal were considered homozygously deleted [16] . To assess the sensitivity of differential PCR for homozygous deletions, we performed a titration experiment with various ratios of normal DNA and DNA from A172 glioma cells with homozygous co-deletion of the p16 INK4a and p14 ARF genes. The chosen threshold value of 0.2 allows the detection of homozygous deletions in the presence of approximately 30% normal DNA for p16 INK4a and 25% for p14 ARF [16] .
Immunohistochemistry
Protein expression was assessed immunohistochemically, using a polyclonal antihuman p14 ARF antibody (FL-132: SC1661; Santa Cruz Biotechnology, Santa Cruz, Calif., USA) and monoclonal antibodies to p16 INK4a (F-12: SC1661; Santa Cruz Biotechnology) and pRB (clone G3-245; PharMingen, San Diego, Calif., USA). Details on the conditions have been reported previously [25] . For p14 ARF , p16 INK4a and pRB immunostaining, reactivity was recorded as negative when ! 5% of cancer cells demonstrated staining, in agreement with a previous study [21] .
Statistical Methods
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Clinicopathological Factors and Gene Alterations
We examined each tumor sample for potential causal relationships by comparing genetic and epigenetic alterations with clinicopathological parameters. As shown in table 2 , tumors with p16
INK4a alterations, mainly hypermethylation, were significantly larger (p = 0.0023). In cases with a previous history of chronic thyroid disease, lymphocytic infiltration was a significant finding (p = 0.0009), together with p14 ARF alterations (p = 0.0475) and infrequent metastases to regional lymph nodes (p = 0.0136). 
Discussion
Activated MAP kinase signaling caused by RET rearrangement, BRAF or RAS mutations, or other molecular alterations, is thought to be essential for the genesis of PTC [11] . However, the frequencies of the above-described gene alterations vary according to ethnicity. For example, rearrangements of the RET proto-oncogene in PTCs are relatively frequent [2, 3] , although prevalence varies considerably (3-36%) in Japan [4] [5] [6] , and other mechanisms of tumor development and PTC progression need to be clarified. The role of DNA hypermethylation in tumor suppressor or DNA repair genes in carcinogenesis has been highlighted. Therefore, we aimed to examine the methylation status of five implicated genes and homozygous deletions of p14 ARF and p16 INK4a and to correlate them with clinicopathological factors.
Cell proliferation is regulated by a family of CDKs, and p16 INK4a is a CDKI which specifically inhibits CDK4/6 and consequently cyclin D-dependent phosphorylation of Rb, leading to less transcription of E2F-responsive genes necessary for S-phase entry [26] . Deregulation of the p16
INK4a gene product through loss of heterozygosity, promoter hypermethylation and/or mutations in the INK4a/ARF locus is a common phenomenon in the transformation process, which is often found in more aggressive tumors [27] . In this study, the frequency of p16 INK4a hypermethylation of PTC was found to be 38.5%, in line with a previous study [12] . Interestingly, in the 15 cases with p16
INK4a alterations, consisting of 14 with hypermethylation and only 1 with homozygous deletions, tumors were significantly larger (T3 and T4), suggesting that p16
INK4a alterations in PTCs are associated with tumor growth or progression, but not tumor development. There was no association between p16 INK4a alterations and clinical stage in this study. For the TNM classification of PTC, age is thought to be an important factor; patients below 45 years of age without distant metastases are grouped in stage I, irrespective of the tumor size and the presence of lymph node metastases. pRB (RB1 gene products) is a negative regulator of cell proliferation, and in a hypophosphorylated state, pRb exerts its antiproliferative function by sequestering and altering the function of the E2F family of transcription factors that control the expression of a bank of genes essential for cells to progress from G1 to the S phase [27] . The importance of RB1 in cancer development is well established, and most human cancers show somatic alterations, either in pRB or other components of the pathway [28] . To our knowledge, we were the first to report RB1 hypermethylation in PTCs, and a relatively high frequency was detected (23.1%), though previous immunohistochemical studies of RB expression in PTCs gave conflicting results [29, 30] . In our previous study, a clear correlation between RB1 alterations and immunohistochemical expression was noted [15] . The present findings suggest that the RB1 gene might play a role in thyroid tumorigenesis, although no significant association between RB1 gene methylations and clinicopathological factors was revealed. An inverse correlation between p16
INK4a and RB1 expression was found, demonstrating that each of the alterations can lead to cancer formation [31] . With respect to the association between p16
INK4a alterations and cancer growth, further studies including other mechanisms of pRB loss are required to establish the hypothesis that alterations in the p16 INK4a / RB1 pathway induce cancer growth in PTCs. p14 ARF plays a major role in the p53 pathway by binding specifically to MDM2, resulting in stabilization of both p53 and MDM2 [32] . p27 Kip1 encodes a cyclin kinase inhibitor, which acts as a potent tumor suppressor gene in a variety of human cancers [33] . O 6 -MGMT encodes a DNA repair protein, and prevents mutations and cell death that result from aberrant alkylation of DNA [34] . With regard to hypermethylation of p14 ARF , p27 Kip1 and O 6 -MGMT in PTCs, the frequencies found here were low (2.6, 15.4 and 15.5%, respectively), and there was no link with clinicopathological factors, indicating that inactivation of these genes is not a major incidence in PTC tumorigenesis. Thyroid neoplasms, including PTCs, exhibit significantly decreased p27 Kip1 expression [35] , especially in nonmetastasizing PTCs [36] , but this is presumably due to other mechanisms.
Our cases with a previous history of chronic thyroid disease demonstrated significant lymphocytic infiltration in otherwise normal parenchyma adjacent to the cancers. Of particular interest, there was a significant association between chronic thyroid disease and p14 ARF alterations or lack of regional lymph node metastasis. Two of the 4 cases with p14 ARF alterations had a past history of chronic thyroid disease. In general, gastric cancers exhibit a high level of aberrant CpG island methylation, and gastritis with marked infiltration of mononuclear cells also displays a number of alterations in genes like p14 ARF , suggesting that chronic inflammation may be closely associated with increased methylation in nonneoplastic gastric mucosa [37] . Similarly, higher frequencies of p14 ARF hypermethylation have been reported in ulcerative colitis-associated colorectal carcinomas and nonneoplastic ulcerative colitis mucosa than in normal colonic mucosa [38] . Although our study included only a small number of cases with chronic thyroid disease, p14 ARF alterations are involved in chronic inflammationrelated PTCs . An association between lymphocyte infiltration and tumor progression has also been reported [39] [40] [41] , and lymphocytes may help to interrupt tumor growth immunologically in the absence of regional lymph node metastasis.
Additionally, immunohistochemically 14 cases (35.9%) expressed RET, showing clear nuclear and cytoplasmic staining, in contrast to a previous study [42] , with no significant association with changes at the gene level and clinicopathological factors (data not shown). Polyclonal antibody against RET recognizes both rearranged and mutated RET oncogene proteins, and a previous report demonstrated a significant correlation between immunohistochemical RET overexpression and RET rearrangement, which was confirmed by RT-PCR [43] . A recent report showed that positive staining does not necessarily mean the presence of a rearrangement [44] , and associations between RET rearrangement and clinicopathological factors or gene alterations require further evaluation.
Recent reports have indicated that BRAF mutations can be detected in 0-80% of PTCs, as alternative events to RET rearrangement [7] [8] [9] [10] . Others have reported early RASSF1A hypermethylation and mutual exclusion with BRAF mutations in PTCs, and it is conceivable that BRAF or Ras mutations, RET rearrangements and RASSF1A hypermethylation could complete the panel of genetic and epigenetic alterations responsible for PTC generation [45] . Our results indicate that of the p16
INK4a alterations, mainly hypermethylation may be associated with tumor progression, and regarding chronic inflammation-related PTCs, p14 ARF alteration may be a key issue.
